The current request of WTO LDC Members for an unconditional extension of the time period within which they must become compliant with the TRIPS Agreement covers all forms of intellectual property protection under TRIPS. Even...
Read MoreOver 130 academics from around the world have signed a letter supporting the unconditional extension of the transition period within which least development country Members of the WTO must become fully compliant with the TRIPS...
Read More[Cross posted from Equilibri.net] Although access to medicines activists have been wise to focus our attention intently on convincing low- and middle-income countries to adopt and use all possible TRIPS-compliant flexibilities...
Read MoreSeveral of IP justice academics are soliciting signatures from legal and other academics around the world who focus on human rights, intellectual property, trade, and development and who are in favor of the request by WTO least...
Read MoreNovartis, its fellow Big Pharma multinationals, Chambers of Commerce, and PhRMA have all roundly denounced India’s Supreme Court’s decision invalidating Novartis’ patent application for Glivec (Gleevec in the...
Read MoreIn a stunning victory for poor patients throughout the developing world, the Indian Supreme Court today ruled against a Novartis challenge of a denial of a patent on its cancer medicine Glivec.[1] The Court upheld strict...
Read MoreIntroduction: On February 27, the Medicines Patent Pool (MPP) and ViiV Healthcare UK Limited (ViiV) announced their License Agreement on an older antiretroviral (ARV), abacavir (ABC), for pediatric treatment only, in 118...
Read MoreLed by Haiti, least developed country Members of the WTO have on November 5 filed a so-called “properly motivated” request under Art. 66.1 of the TRIPS Agreement for a collective extension of the transition period...
Read MoreIt is a tremendous victory for people living with HIV in Indonesia that it has issued new compulsory licenses on seven anti-retroviral medicines, allowing the government to access generic versions of those medicines –...
Read MoreProposed Pan-African IP Organization a Terrible Idea In a stunning development, following an obscure vote of Heads of State at the Africa Union in 2007 (Assembly Council/AU/Dec. 138(VIII)), the AU Scientific, Technical, and...
Read MoreThe leaked Trans-Pacific Partnership Investment Chapter has been analyzed extensively with respect to its dangerous intellectual property protections and enhanced enforcement mechanisms and its equally dangerous extra-judicial...
Read More[Reposted from treatpeopleright.org] “Treating people right” means many things, but one of the things it means is that people living with and at risk of HIV/AIDS must have immediate and affordable access to new medicines,...
Read MoreIn testimony before the U.S. House of Representatives Subcommittee on Intellectual Property, Competition and the Internet on 27 June 2012 (Hearing: Protecting Patents, Trade Secrets, and Market Access), the Deputy Director of...
Read MoreJust as Novartis appealed from an order denying its patent application on Glivec, Bayer has now appealed the granting of a compulsory license on Nexavar. Rather than honestly state that it likes selling its cancer medicines for...
Read MoreFifty AIDS activists, students, and community group members protested at Novartis’s Institute for BioMedical Research in Cambridge, Massachusetts, on February 22, the eve of the Swiss pharmaceutical company’s annual...
Read MoreThe Treatment Action Campaign has issued a Briefing providing a great summary of the campaign launched last year trying to convince/force the S. Africa government to adopt TRIPS-compliant flexibilities in its patent regime and...
Read More
Comments on: Civil Society Documents Comments on: industry | infojustice